2,858 reports of this reaction
1.6% of all SARILUMAB reports
#11 most reported adverse reaction
HEPATIC ENZYME INCREASED is the #11 most commonly reported adverse reaction for SARILUMAB, manufactured by Sanofi-Aventis U.S. LLC. There are 2,858 FDA adverse event reports linking SARILUMAB to HEPATIC ENZYME INCREASED. This represents approximately 1.6% of all 183,830 adverse event reports for this drug.
Patients taking SARILUMAB who experience hepatic enzyme increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATIC ENZYME INCREASED is a less commonly reported adverse event for SARILUMAB, but still significant enough to appear in the safety profile.
In addition to hepatic enzyme increased, the following adverse reactions have been reported for SARILUMAB:
The following drugs have also been linked to hepatic enzyme increased in FDA adverse event reports:
HEPATIC ENZYME INCREASED has been reported as an adverse event in 2,858 FDA reports for SARILUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATIC ENZYME INCREASED accounts for approximately 1.6% of all adverse event reports for SARILUMAB, making it a notable side effect.
If you experience hepatic enzyme increased while taking SARILUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.